Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

Dr. Christopher Seet, an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA, has received a $2.9 million R37 MERIT Award from the National Cancer Institute to advance the development of innovative T cell therapies for cancer. 

Dr. Aditya Bardia has been named Editor-in Chief of the peer-reviewed journal Breast Cancer Research and Treatment, a comprehensive publication dedicated to advancing the understanding and management of breast cancer. 

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), hosts the 47^th annual San Antonio Breast Cancer Symposium on Dec. 10-13 in downtown San Antonio. Owned and initiated by Mays Cancer Center, the San Antonio Breast Cancer Symposium is the world’s largest breast cancer research conference where more than 11,000 clinicians, researchers, and patient advocates from more than 102 countries are expected to attend.

Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease – a liver-specific type and a systemic type that affects other organs and tissues. The discovery could lead to improved diagnosis and treatment of this growing patient group. Two studies are published back-to-back in Nature Medicine.

New research from the University of Ottawa sees mRNA and RNAi-based therapies delivered in single treatment, paving way for treatment of cancer, cardiovascular diseases.